炎症体
NLRC4型
目标2
上睑下垂
生物
错义突变
先天免疫系统
半胱氨酸蛋白酶1
突变体
突变
吡喃结构域
免疫学
炎症
细胞生物学
免疫系统
遗传学
基因
作者
Scott Canna,Adriana A. de Jesus,Sushanth Gouni,Stephen R. Brooks,Bernadette Marrero,Yin Liu,Michael A. DiMattia,Kristien J.M. Zaal,Gina A. Montealegre Sanchez,Hanna Kim,Dawn Chapelle,Nicole Plass,Yan Huang,Alejandro V. Villarino,Angélique Biancotto,Thomas A. Fleisher,Joseph A. Duncan,John J. O’Shea,Susanne M. Benseler,Alexei A. Grom,Zuoming Deng,Ronald M. Laxer,Raphaela Goldbach‐Mansky
出处
期刊:Nature Genetics
[Springer Nature]
日期:2014-09-14
卷期号:46 (10): 1140-1146
被引量:642
摘要
Scott Canna and colleagues report the identification of a de novo mutation in a conserved region of NLRC4 by whole-exome sequencing of an individual presenting with macrophage activation syndrome. Functional studies confirm that the mutation leads to constitutive inflammasome activation. Inflammasomes are innate immune sensors that respond to pathogen- and damage-associated signals with caspase-1 activation, interleukin (IL)-1β and IL-18 secretion, and macrophage pyroptosis. The discovery that dominant gain-of-function mutations in NLRP3 cause the cryopyrin-associated periodic syndromes (CAPS) and trigger spontaneous inflammasome activation and IL-1β oversecretion led to successful treatment with IL-1–blocking agents1. Herein we report a de novo missense mutation (c.1009A>T, encoding p.Thr337Ser) affecting the nucleotide-binding domain of the inflammasome component NLRC4 that causes early-onset recurrent fever flares and macrophage activation syndrome (MAS). Functional analyses demonstrated spontaneous inflammasome formation and production of the inflammasome-dependent cytokines IL-1β and IL-18, with the latter exceeding the levels seen in CAPS. The NLRC4 mutation caused constitutive caspase-1 cleavage in cells transduced with mutant NLRC4 and increased production of IL-18 in both patient-derived and mutant NLRC4–transduced macrophages. Thus, we describe a new monoallelic inflammasome defect that expands the monogenic autoinflammatory disease spectrum to include MAS and suggests new targets for therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI